Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. (2021)
Journal Article
Tree, J., Turnbull, J., Buttigieg, K., Elmore, M., Coombes, N., Hogwood, J., Mycroft-West, C., Andrade De Lima, M., Skidmore, M., Karlsson, R., Chen, Y.-H., Yang, Z., Spalluto, C., Staples, K., Yates, E., Gray, E., Singh, D., Wilkinson, T., Page, C., & Carroll, M. (2021). Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. British Journal of Pharmacology, 178, 626--635. https://doi.org/10.1111/bph.15304

BACKGROUND AND PURPOSE: Currently, there are no licensed vaccines and limited antivirals for the treatment of COVID-19. Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID-19 patients. Additionally, in the Uni... Read More about Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations..

Identification of heparin modifications and polysaccharide inhibitors of Plasmodium falciparum merozoite invasion that have potential for novel drug development. (2017)
Journal Article
Boyle, M. J., Skidmore, M., Dickerman, B., Cooper, L., Devlin, A., Yates, E., Horrocks, P., Freeman, C., Chai, W., & Beeson, J. G. (2017). Identification of heparin modifications and polysaccharide inhibitors of Plasmodium falciparum merozoite invasion that have potential for novel drug development. Antimicrobial Agents and Chemotherapy, 61(11), https://doi.org/10.1128/AAC.00709-17

Despite recent successful control efforts, malaria remains a leading global health burden. Alarmingly, resistance to current antimalarials is increasing, and the development of new drug families is needed to maintain malaria control. Current antimala... Read More about Identification of heparin modifications and polysaccharide inhibitors of Plasmodium falciparum merozoite invasion that have potential for novel drug development..